Dhanuka Agritech Limited has announced its financial results for the quarter and year ended March 31, 2026. The company reported annual revenue of ₹2,01,978.96 lakhs and a net profit of ₹28,723.49 lakhs for the fiscal year. Additionally, the Board approved a share buyback plan of up to ₹70 crore, recommended a final dividend of 100% (₹2 per share), and unveiled plans for international business expansion into Europe and Brazil.
Financial Highlights for FY 2025-26
For the financial year ended March 31, 2026, Dhanuka Agritech Limited achieved a total revenue from operations of ₹2,01,978.96 lakhs. The profit for the period stood at ₹28,723.49 lakhs, with a basic earnings per share (EPS) of ₹63.72. Performance remained strong in the final quarter, contributing ₹9,777.06 lakhs to the annual net profit.
Strategic Capital Allocation and Buyback
The Board has approved a buyback proposal of up to 5,00,000 fully paid-up equity shares at a price of ₹1,400 per share, representing an aggregate investment of ₹70 crore. The record date for determining eligible shareholders for the buyback has been set for Friday, May 29, 2026. Furthermore, the Board recommended a final dividend of 100%, equating to ₹2 per equity share, subject to shareholder approval at the upcoming 41st Annual General Meeting scheduled for August 3, 2026.
International Growth and Expansion
In a move to strengthen its global footprint, the company received approval to establish Wholly Owned Subsidiaries or acquire shares in entities based in Europe and Brazil. These strategic investments, with an initial allocation of ₹1 crore per entity, are designed to facilitate business growth, support brand registrations, and transfer rights acquired from Bayer. This expansion aligns with the company’s objective to enhance its market presence outside India.
New Employee Benefit Initiatives
Dhanuka Agritech is introducing the Employee Stock Option Plan 2026 and a Stock Appreciation Rights Plan 2026. These schemes aim to incentivize designated employees through the grant of up to 50,000 equity options and 1,25,000 Stock Appreciation Rights, respectively, subject to performance-based criteria and shareholder approval.
Source: BSE
